Atavistik Bio is a biotechnology company that develops precision allosteric small molecules aimed at treating metabolic diseases and cancer.
Atavistik Bio has raised $40.0M in total funding. The most recent round was Series B. The last funding was announced in March 2026.
Atavistik Bio's investors include RA Capital Management, Lux Capital, The Column Group, Nextech Invest, Regeneron Ventures.
Atavistik Bio is headquartered in Cambridge, United States.
Atavistik Bio is a biotechnology company that develops precision allosteric small molecules aimed at treating metabolic diseases and cancer.
Atavistik Bio is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Atavistik Bio — Funding & Investors." VCBacked, March 5, 2026, https://www.vcbacked.co/company/atavistik-bio. Accessed August 15, 2026.
VCBacked. (2026). Atavistik Bio — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/atavistik-bio
{{cite web |title=Atavistik Bio — Funding & Investors |url=https://www.vcbacked.co/company/atavistik-bio |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated